Results 141 to 150 of about 8,117 (271)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

Journal of Asthma and Allergy, 2019
J Mark FitzGerald,1 Eugene R Bleecker,2 Arnaud Bourdin,3 William W Busse,4 Gary T Ferguson,5 Laura Brooks,6 Peter Barker,6 Ubaldo J Martin6 1Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung ...
FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, Barker P, Martin UJ   +7 more
doaj  

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series [version 1; peer review: 2 approved]

F1000Research, 2023
Background: Severe eosinophilic asthma (SEA), one of the phenotypes of asthma that is characterized by elevated blood eosinophil counts, is a common cause of uncontrolled asthma.
Priti Meshram, Soumya Das, Nagarjuna Maturu, Rahul Sharma, Deepak Talwar, Manoj Yadav   +5 more
doaj  

重症好酸球性喘息におけるベンラリズマブの3次元コンピュータ断層画像解析への影響 [PDF]

新潟大学Niigata University博士（医学）Introduction: Benralizumab, an anti-interleukin-5 receptor chain monoclonal antibody, is used to treat severe asthma and control asthma symptoms or exacerbations.
Tsubokawa, Fumito, 坪川, 史人
core   +1 more source

Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma [PDF]

, 2019
Andrea Matucci, Enrico Maggi, Alessandra Vultaggio   +2 more
openalex   +1 more source

Benralizumab for severe DRESS in two COVID-19 patients [PDF]

The Journal of Allergy and Clinical Immunology: In Practice, 2021
Schmid-Grendelmeier, Peter, Steiger, Peter, Naegeli, Mirjam C., Kolm, Isabel, Lang, Claudia Cécile Valérie, Maverakis, Emanual, Brüggen, Marie-Charlotte   +6 more
openaire   +4 more sources

Benralizumab for the treatment of severe eosinophilic asthma [PDF]

Prescriber, 2018
Benralizumab (Fasenra) is a new anti‐interleukin‐5 monoclonal antibody therapy for the management of severe uncontrolled eosinophilic asthma. This article discusses its properties, clinical trial efficacy and adverse effects.
openaire   +2 more sources

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab

International Journal of COPD, 2019
Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of ...
George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, Ramsheh MY, Richardson M, van der Merwe R, Martin U, Newbold P, Brightling CE   +11 more
doaj  

Eosinophilic cystitis treatment with benralizumab [PDF]

Journal of Allergy and Clinical Immunology, 2020
W. Donald Cooke, Abigail J Tarr Cooke
openaire   +2 more sources

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

Biologics: Targets & Therapy, 2019
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona ...
Caminati M, Bagnasco D, Vaia R, Senna G
doaj  

Tolerance to acetyl-salicylic acid in NSAID-exacerbated respiratory disease after biological therapies with benralizumab, dupilumab, mepolizumab or omalizumab. [PDF]

, 2023
Juan C. López, Elizabeth Garcia, Ana Maria Calle Alvarez, Jefferson-Antonio Buendía, Jorge Sánchez   +4 more
openalex   +1 more source